checkAd

    EQS-News  445  0 Kommentare CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

    Issuer: CureVac / Key word(s): Study
    CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features)

    30.01.2023 / 13:00 CET/CEST
    The issuer is solely responsible for the content of this announcement.


    CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs

     

    • Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and flu
    • COVID-19: monovalent modified mRNA construct CV0501 successfully boosted antibody titers against BA.1 and ancestral variants in adults age ≥65
    • Flu: monovalent modified mRNA construct Flu-SV-mRNA elicited antibodies approximately 2.3 times those of licensed vaccine comparator in adults aged 60-80
    • Reaffirming plan to advance modified mRNA COVID-19 and flu candidates to the next stages of clinical development in collaboration with GSK in 2023

    TÜBINGEN, Germany/ BOSTON, USA – January 30, 2023 – CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced positive extended preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu conducted in collaboration with GSK. The newly reported data focus on older adult age groups in both indications. Detailed data can be reviewed in the associated presentation. The data further support the decision to advance updated versions of the modified mRNA COVID-19 and flu vaccine constructs to the next stage of clinical testing in 2023.

    “The exciting preliminary data seen among older adults for our COVID-19 and flu programs significantly add to the validation of our technology platform into this highly relevant and at-risk population,” said Franz-Werner Haas, Chief Executive Officer of CureVac. “The strong immune responses we observed in both indications further support our commitment to advancing to the next stage of product development in 2023.”

    Seite 1 von 5


    Diskutieren Sie über die enthaltenen Werte


    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    EQS-News CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs Issuer: CureVac / Key word(s): Study CureVac Announces Positive Data in Older Adults from COVID-19 and Flu mRNA Vaccine Development Programs (news with additional features) 30.01.2023 / 13:00 CET/CEST The issuer is solely responsible for the …

    Schreibe Deinen Kommentar

    Disclaimer